 "Indoco Remedies zooms over 30% in two-days on strong Q1 earnings")
Indoco Remedies has surged 17% to Rs 256, extending its previous day’s 14% rally, after reported an over two-fold jump in net profit at Rs 20 crore for the first quarter ended June 2014 (Q1), on back of strong operational performance. The pharmaceuticals company had profit of Rs 9 crore in the same quarter last fiscal.
The company’s net sales grew 29% to Rs 199 crore during the quarter under review against Rs 154 crore in the corresponding quarter of previous year.
The growth was driven by both exports and domestic, which posted a year-on-year (yoy) growth of 58.8% and 23.1% respectively. The domestic formulation sales grew by 24.4% yoy, much higher than the Industry growth of 8.8% yoy.
On the operating front, the OPM’s came in 18.1% V/s 16.2% expected and an expansion of 560 basis points yoy, mainly on back of the gross margins, which expanded by 365 basis points yoy to end the period at 63.3% V/s 59.7% during the last corresponding period, says analyst at Angel Broking in a client note.
The stock opened at Rs 219 and touched a record high of Rs 259 on NSE. The trading volumes on the counter surged more than two-fold with a combined 3.13 million shares changed hands so far on NSE and BSE.
The company’s net sales grew 29% to Rs 199 crore during the quarter under review against Rs 154 crore in the corresponding quarter of previous year.
The growth was driven by both exports and domestic, which posted a year-on-year (yoy) growth of 58.8% and 23.1% respectively. The domestic formulation sales grew by 24.4% yoy, much higher than the Industry growth of 8.8% yoy.
On the operating front, the OPM’s came in 18.1% V/s 16.2% expected and an expansion of 560 basis points yoy, mainly on back of the gross margins, which expanded by 365 basis points yoy to end the period at 63.3% V/s 59.7% during the last corresponding period, says analyst at Angel Broking in a client note.
The stock opened at Rs 219 and touched a record high of Rs 259 on NSE. The trading volumes on the counter surged more than two-fold with a combined 3.13 million shares changed hands so far on NSE and BSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%